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The JAK2V617F mutation has been identiﬁed in most patients with myeloproliferative neoplasms
(MPNs), including polycythemia vera, essential thrombocythemia and primary myeloﬁbrosis.
Although JAK2V617F is the predominant allele associated with MPNs, other activating Janus kinase
2 (JAK2) alleles (such as K539L, T875N) also have been identiﬁed in distinct MPNs. The basis for the
differences in the in vivo effects of different JAK2 alleles remains unclear. We have characterized
three different classes of disease-associated JAK2 mutants (JAK2V617F, JAK2K539L and JAK2T875N)
and found signiﬁcant differences in biochemical, signaling and transforming properties among
these different classes of JAK2 mutants.
Structured summary of protein interactions:
EpoR physically interacts with Jak2 by anti bait coimmunoprecipitation (View Interaction 1, 2, 3)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction region (JH4–JH7), which is required for association with cytokineJanus Kinase 2 (JAK2) is a member of the Janus family of non-
receptor protein tyrosine kinases, which also includes JAK1, JAK3
and TYK2. JAK2 serves as a key mediator of cytokine receptor sig-
naling and plays an important role in hematopoiesis [1,2]. JAK2 is
the predominant JAK kinase activated in response to erythropoi-
etin (Epo), thrombopoietin (Tpo), interleukin (IL)-3, granulocyte/
macrophage colony stimulating factor (GM-CSF), IL-5, growth
hormone and prolactin [3–10]. It is also activated along with
other JAKs in responses to a wide variety of cytokines including
interferon c (IFNc), stem cell factor (SCF), granulocyte colony
stimulating factor (G-CSF), IL-6, IL-11, IL-12, IL-19, IL-20, IL-23,
IL-24, IL-27, IL-31, leukemia inhibitory factor (LIF), ciliary neuro-
trophic factor (CNTF), cardiotrophin-1 (CT-1) and oncostatin M
(OSM) [11–16]. JAK2 contains seven JAK homology domains
(JH1–JH7), which include a catalytically active kinase domain
(JH1) and a catalytically inactive pseudo-kinase domain (JH2).
The JH2 domain is thought to play a negative auto-regulatory
role in that deletion of the JH2 domain results in constitutive
activation of the JAK2 kinase [17]. JAK2 also contains a FERM
(band 4.1, ezrin, radixin, moesin) domain in the N-terminalchemical Societies. Published by E
oietin; EpoR, erythropoietin
lycythemia vera; ET, essentialreceptors [18].
A somatic point mutation (V617F) in the pseudo-kinase (JH2)
domain of JAK2 has been found in most patients with polycythe-
mia vera (PV) and 50–60% patients with essential thrombocythe-
mia (ET) and primary myeloﬁbrosis [19–23]. JAK2V617F is a
constitutively active tyrosine kinase, which can transform hemato-
poietic cell lines and progenitors [19,20,24]. Expression of
JAK2V617F mutant activates multiple downstream signaling path-
ways, such as, Stat5, Stat3, Erk/MAP kinase and PI3 kinase/Akt
pathways [19,24]. Expression of JAK2V617F also confers hypersen-
sitivity to Epo [19,20,24], which is a characteristic feature of PV. It
has been shown that co-expression of a homodimeric type I cyto-
kine receptor is required for JAK2V617F-mediated transformation
of hematopoietic cells [25]. Transgenic or knock-in mice models
of JAK2V617F showed that JAK2V617F is directly responsible and
sufﬁcient to cause PV [24,26–30].
Additional mutations in JAK2 also have been observed in hema-
tologic diseases with a much lesser frequency than JAK2V617F.
Several mutations in the JAK2 exon 12 including JAK2K539L have
been identiﬁed in a small number of patients with PV and idio-
pathic erythrocytosis [31,32]. Unlike JAK2V617F, which occurs in
a wide spectrum of myeloid malignancies, JAK2 exon 12 mutations
are only observed in JAK2V617F-negative PV with isolated erythro-
cytosis without concomitant leukocytosis or thrombocytosis, sug-
gesting that JAK2 exon 12 mutations are associated with a
distinct clinical phenotype. Another activating mutation in the
kinase domain (JH1) of JAK2 (JAK2T875N) has been identiﬁed inlsevier B.V. All rights reserved.
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leukemia (AMKL) [33]. Although frequency of this mutation in
AMKL is yet to be determined, expression of JAK2T875N induced
a myeloproliferative neoplasm (MPN) with features of AMKL in a
murine bone marrow transplantation (BMT) assay [33]. In addition,
IREED deletion or substitutions in the conserved R683 residue
within the JH2 domain of JAK2 have been identiﬁed in Down’s syn-
drome-associated acute lymphoblastic leukemia [34,35]. Thus, dif-
ferent activating JAK2 alleles are associated with different
phenotypes. However, the basis for the differences in the in vivo ef-
fects of different JAK2 alleles remains unclear.
Here, we hypothesized that different JAK2 mutants have dis-
tinct intrinsic transforming ability, and their biochemical and sig-
naling properties may differ. To test this, we have analyzed the
biochemical, signaling and biological properties of three classes/
types of disease-associated JAK2 mutants, JAK2V617F (located in
the JH2 pseudo-kinase domain), JAK2K539L (located in the linker
region between JH2 and JH3 domains) and JAK2T875N (located
in the JH1 kinase domain). We observed signiﬁcant differences in
biochemical, signaling and transforming properties within these
three classes of JAK2 mutants.2. Materials and methods
2.1. Plasmids and reagents
The cDNA encoding murine JAK2 was obtained from Dr. James
Ihle (St. Jude Children’s Hospital, TN). JAK2V617F, JAK2K539L and
JAK2T875N mutants were generated using the Quick Change site-
directed mutagenesis kit (Stratagene) and sub-cloned into MSCV-
IRES-GFP vector. The monoclonal anti-phosphotyrosine antibody
(4G10) was purchased from Millipore. The rabbit antibodies direc-
ted against phospho-JAK2 (Y1007/Y1008), phospho-Stat5 (Y694),
phospho-Stat3 (Y705), phospho-Akt (S473), phospho-Erk1/2, phos-
pho-Shp2 and phospho-Gab2 were purchased from Cell Signaling
Technologies, and the rabbit antibodies against JAK2, Stat5, Stat3,
Akt, Erk2, Shp2, Pim-1, Pim-2 and erythropoietin receptor (EpoR)
were obtained from Santa Cruz Biotechnology.
2.2. Cell culture and proliferation assay
Ba/F3-EpoR cells were maintained in RPMI medium containing
10% FBS and IL-3 (1 ng/ml). To generate Ba/F3-EpoR cells stably
expressing different JAK2 mutants, Ba/F3-EpoR cells were trans-
duced with MSCV-IRES-GFP retroviruses expressing JAK2WT,
JAK2V617F, JAK2K539L or JAK2T875N, and sorted for GFP positive
cells. For proliferation assays, cells were washed three times in
RPMI medium containing 10% FBS (without any cytokine) and
seeded in a 96-well plate (2.5  103 per well). Cell proliferation
was measured at 24 h, 48 h and 72 h after plating using the WST
assay.
2.3. Retroviral transduction and colony forming assay
High-titer retroviral stocks of WT or mutant JAK2 were pre-
pared by transient transfection of 293T cells as described previ-
ously [36]. Bone marrow cells from wild type C57/BL6 mouse
were transduced with retroviruses expressing WT or mutant
JAK2 by two rounds of spininfection [36] and plated (1  104 per
dish) in duplicates in methylcellulose medium without any cyto-
kine (M3234, Stem Cell Technologies). CFU-E colonies were
counted after 2 days by morphology and staining with benzidine
solution (Sigma). In some experiments, Ba/F3-EpoR cells express-
ing different JAK2 mutants were assayed for colony formation in
methylcellulose medium without any cytokine.2.4. Immunoprecipitation and immunoblotting
Ba/F3-EpoR cells expressing different JAK2 mutants were de-
prived of IL-3 for 24 h and then starved for 6 h in RPMI medium
containing 0.5% BSA at 37 C. Cells were washed in PBS and lysed
in 1% Triton X-100 buffer containing 50 mM Tris–HCl, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 2 mM Na3VO4, 5 mM NaF sup-
plemented with protease inhibitor cocktail (Sigma). Cell lysates
were subjected to immunoprecipitation with anti-EpoR afﬁnity re-
sin and probed with anti-JAK2 or anti-EpoR antibodies. To detect
phosphorylated signaling proteins, cells lysates were separated
by SDS–PAGE. Immunoblotting was performed using phospho-
speciﬁc antibodies as indicated. To control for loading, blots were
re-probed with antibodies against total proteins.
2.5. In vitro JAK2 kinase assay
The cells were lysed in 1% Triton X-100 lysis buffer supple-
mented with protease inhibitors. JAK2 was immunoprecipitated
from the cell lysates using anti-JAK2 antibody. Immunoprecipitates
were washed three times with lysis buffer and twice with kinase
buffer (10 mM HEPES [pH 7.4], 50 mM NaCl, 5 mM MnCl2, 5 mM
MgCl2, 1 mM Na3VO4, 5 mM NaF, 1 mM dithiothreitol plus prote-
ase inhibitors). The immunecomplex was resuspended in kinase
buffer supplemented with 10 lM ATP, 2 lCi [c-32P] ATP (Perkin
Elmer). A peptide derived from Stat5 (AKAADGY694VKPQIKQVV)
containing the JAK2 phosphorylation site was used as a substrate.
The reaction mixture was incubated with 0.5 mM Stat5 peptide
substrate at 30 C for 30 min. Reactions were terminated by
addition of an equal volume of 20 mM EDTA. An aliquot of the reac-
tion mixture was transferred onto P81 phosphocellulose paper
(Whatman). After washing the P81 paper three times with 0.75%
phosphoric acid, bound radioactivity was measured using a Scintil-
lation Counter. The counts detected in the absence of peptide were
used as a background.
2.6. Statistical analysis
Results are expressed as mean plus or minus SEM, and data
were analyzed by the two-tailed Student’s t test. P < 0.05 was con-
sidered to be statistically signiﬁcant.3. Results
3.1. Kinase activity of disease-associated JAK2 mutants
We analyzed three disease-associated JAK2 mutants,
JAK2V617F, JAK2K539L and JAK2T875N located in the JH2 pseudo-
kinase domain, the linker region between JH2 and JH3 domains,
and the JH1 kinase domain respectively (as depicted in Fig. 1A).
We established Ba/F3-EpoR cell lines stably expressing wild type
JAK2 (JAK2WT), JAK2V617F, JAK2K539L and JAK2T875N mutants.
To assess the kinase activity of these JAK2mutants, cell lysateswere
immunoprecipitated with anti-JAK2 antibody and the immunopre-
cipitated JAK2 kinases were incubated with the Stat5 peptide con-
taining the JAK2 phosphorylation site. As expected, very little
kinase activity was seen with vector transfected Ba/F3-EpoR cells
(Fig. 1B). All three disease-associated JAK2 mutants were more ac-
tive than the JAK2WT (Fig. 1B). JAK2T875N exhibited the highest
levels of kinase activity among these three classes of JAK2 mutants.
JAK2V617Fwasmore active than the JAK2K539L but less active than
the JAK2T875N mutant (Fig. 1B). However, the levels of expression
of JAK2were comparable in cells expressing different JAK2mutants
(Fig. 1B, lower panel). Thus, different classes of disease-associated
JAK2 mutants may have different levels of catalytic activity.
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Fig. 1. Catalytic activities of disease-associated JAK2 mutants. (A) Schematic
structure of JAK2 and the locations of the disease-associated JAK2 mutants used
in this study. (B) Mutant JAK2 proteins were immunoprecipitated and subjected to
an in vitro kinase assay using a Stat5-derived peptide as a substrate. Phosphory-
lated peptides were measured by a scintillation counter (upper panel). Note that
JAK2T875N mutant exhibited signiﬁcantly more kinase activity than JAK2V617F
(P < 0.005) or JAK2K539L mutant (P < 0.005), whereas JAK2V617F showed higher
kinase activity than JAK2K539L (P < 0.005). Cell lysates used for immunoprecipi-
tation were separated by SDS–PAGE and subjected to immunoblotting with anti-
JAK2 antibody (bottom panel) to show equivalent expression of mutant JAK2
proteins.
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To assess the biological effects of JAK2 mutants, we ﬁrst mea-
sured the cytokine-independent proliferation of cells expressing
different classes of JAK2 mutants. As expected, Ba/F3-EpoR cells
expressing vector (GFP) or JAK2WT failed to proliferate in absence
of cytokine (Fig. 2A). Ba/F3-EpoR cells expressing JAK2V617F,
JAK2K539L and JAK2T875N mutants continued to proliferate in ab-
sence of cytokine. However, expression of JAK2T875N resulted in
signiﬁcantly increased proliferation of Ba/F3-EpoR cells compared
with JAK2V617F or JAK2K539L expression (Fig. 2A).
Next we assessed the effects of different JAK2 mutants on clo-
nogenic growth of Ba/F3-EpoR cells. For this purpose, Ba/F3-EpoR
cells expressing different JAK2 mutants were plated in methylcel-
lulose medium without any cytokine, and colonies were counted
after 5–6 days. Expression of the vector (GFP) or JAK2WT failed
to produce any colony in the absence of cytokine, whereas
expression of JAK2 mutants resulted in a large number ofO
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Fig. 2. Biological effects of disease-associated JAK2 mutants. (A) Ba/F3-EpoR cells stably
were plated in triplicates in a 96-well plate in the absence of cytokine, and cell prolifer
(P < 0.01). Note that JAK2T875N-expressing cells exhibited signiﬁcantly more cytokine-in
(B) Clonogenic growth of Ba/F3-EpoR cells expressing different JAK2 mutants was mea
represent the means ± S.E.M. of three independent experiments. Asterisk indicates sign
clonogenic growth of Ba/F3-EpoR cells than cells expressing JAK2V617F (P < 0.005) or JAcytokine-independent colonies (Fig. 2B). Ba/F3-EpoR cells express-
ing JAK2T875N gave rise to the highest number of cytokine-
independent colonies among the three different classes of JAK2
mutants (Fig. 2B), consistent with increased proliferation of cells
expressing JAK2T875N compared to other JAK2 mutants. Together,
these results suggest that different classes of JAK2 mutants have
different levels of biological activity.
3.3. Differential transforming potentials of disease-associated JAK2
mutants
We and other groups have shown that expression of JAK2V617F
in the bone marrow or spleen results in transformation of ery-
throid progenitors [24,26–30]. So, we asked if there is any differ-
ence in the transforming ability of erythroid progenitors among
these three classes of JAK2 mutants. We transduced wild type bone
marrow cells with retroviruses expressing JAK2WT, JAK2V617F,
JAK2K539L and JAK2T875N, and plated in methylcellulose medium
in absence of cytokine. Colony forming unit-erythroid (CFU-E) was
counted after 2 days. For this purpose, all retroviral titers were
determined in Ba/F3 cells based on their GFP expression (Supple-
mentary Fig. 1A), and equivalent titer retroviruses were used for
BM transduction. We observed comparable infection efﬁciency
with different JAK2 mutant retroviruses on BM cells (Supplemen-
tary Fig. 1B). As expected, expression of retroviral vector alone
failed to transform erythroid progenitors (Fig. 3). Overexpression
of JAK2WT in the BM gave rise to a few cytokine-independent
CFU-E colonies. Expression of JAK2V617F and JAK2K539L resulted
in a large number of cytokine-independent CFU-E colonies
(Fig. 3). However, JAK2T875N expression caused signiﬁcantly less
erythroid transformation compared to JAK2V617F and JAK2K539L
mutants (Fig. 3) even though JAK2T875N mutant exhibited the
highest kinase activity (Fig. 1B). We also observed signiﬁcantly lar-
ger number of CFU-E colonies in the presence of Epo in JAK2V617F
and JAK2K539L expressing BM cells compared with JAK2T875N
(Fig. 3). These results suggest that different classes of disease-
associated JAK2 mutants have distinct intrinsic transforming
ability.
3.4. Signaling properties of disease-associated JAK2 mutants
To further study the disease-associated JAK2 mutants, we
examined their effects on cell signaling. First, we analyzed their
effects on overall protein tyrosyl phosphorylation by immunoblot-
ting of cell lysates from the growth factor starved cells using
anti-phosphotyrosyl antibody. Overall tyrosine phosphorylation
of proteins was signiﬁcantly enhanced in cells expressing JAK2N
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expressing GFP (vector), JAK2WT, JAK2V617F, JAK2K539L and JAK2T875N mutants
ation was measured using the WST assay. Asterisk indicates signiﬁcant differences
dependent proliferation compared with cells expressing JAK2V617F and JAK2K539L.
sured in the absence of cytokine in a methylcellulose-based colony assay. Results
iﬁcant differences (P < 0.005). Expression of JAK2T875N caused signiﬁcantly more
K2K539L (P < 0.005).
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135, 125, 120, 90, 88, 71, 68, 55 KDa) exhibited increased tyrosyl
phosphorylation in cells expressing JAK2T875N compared with
JAK2V617F and JAK2K539L (Fig. 4A). Autophosphorylation of
JAK2T875N, as monitored by immunoblotting with phospho-spe-
ciﬁc JAK2 antibody, was signiﬁcantly higher than JAK2V617F and
JAK2K539L mutants (Fig. 4B). However, JAK2V617F was slightly
more autophosphorylated than JAK2K539L mutant (Fig. 4B), con-
sistent with the results of the kinase assays. Phosphorylation/acti-
vation of the downstream targets, such as Stat5 and Stat3, was also
signiﬁcantly higher in cells expressing JAK2T875N compared to
JAK2V617F and JAK2K539L mutants (Fig. 4B). Moreover, expres-
sion of Pim-1 and Pim-2, which are known targets of the JAK/Stat
pathway [37], was signiﬁcantly more induced in JAK2T875N-
expressing cells compared to cells expressing JAK2V617F and
JAK2K539L mutants (Fig. 4B). Expression of JAK2V617F, however,
resulted in higher level of activation of Stat5 and Stat3 than
JAK2K539L expression (Fig. 4B).
We also studied the effects of disease-associated JAK2 mutants
on other downstream signaling molecules and pathways. We ob-
served constitutive phosphorylation of Shp2 and Gab2 in cells
expressing activated JAK2 mutants (Fig. 4C). Phosphorylation of
Shp2 was comparable in cells expressing JAK2V617F and
JAK2T875N mutants. However, phosphorylation of Gab2 was sig-
niﬁcantly higher in JAK2T875N-expressing cells compared to cells
expressing JAK2V617F and JAK2K539L mutants (Fig. 4C). Similarly,
activation of Akt and Erk1/2 were enhanced in cells expressing
JAK2T875N compared to JAK2V617F and JAK2K539L (Fig. 4C).
Thus, different classes of disease-associated JAK2 mutants give rise
to different levels of activation of downstream signaling pathways.
Next, we assessed the interaction of different JAK2 mutants
with the EpoR. To investigate the interaction between different
JAK2 mutants and EpoR, we performed immunoprecipitation
experiments. Compared with the wild type JAK2, activating JAK2
mutants exhibited increased interaction with the EpoR (Fig. 4D).
Notably, JAK2V617F and JAK2K539L mutants showed signiﬁcantly
more interaction with the EpoR compared with the JAK2T875N
mutant (Fig. 4D). Thus, different JAK2 mutants differentially inter-
act with the EpoR. The reduced ability of the JAK2T875N mutant to
interact with the EpoR may possibly explain the reduced trans-
forming potential of erythroid progenitors by the JAK2T875N
mutant.4. Discussion
Different JAK2 mutations are associated with different hemato-
logic disorders, but the basis for various pathologies associated
with different JAK2 mutants has remained unclear. Previous
studies suggested that all disease-associated JAK2 mutants have
increased basal catalytic activity. We have found that disease-
associated JAK2 mutants differ in their catalytic activity, and their
effects on downstream signaling also signiﬁcantly vary. However,
catalytic activity alone cannot explain all mutant JAK2-associated
pathology. We observed that different disease-associated JAK2 mu-
tants have differential ability to transform erythroid progenitors,
which could be due to their differential interaction with the EpoR.
Murine models of JAK2V617F, JAK2K539L and JAK2T875N have
been reported. We and other investigators have shown that phys-
iologic expression of JAK2V617F in murine hematopoietic progen-
itors resulted in a PV-like disease characterized by marked increase
in hemoglobin and hematocrit, increased RBC, leukocytosis, neu-
trophilia, thrombocytosis and splenomegaly [24,29,30]. Expression
of JAK2 exon 12 mutant JAK2K539L resulted in erythrocytosis (in-
creased RBC, hemoglobin and hematocrit [31,38], whereas expres-
sion of JAK2T875N in a murine bone marrow transplant (BMT)model induced a MPN with a megakaryocyte phenotype, including
megakaryocytic hyperplasia, impaired megakaryocyte polyploidi-
zation and increased reticulin ﬁbrosis in the bone marrow and
spleen [33]. JAK2T875N transplanted mice also exhibited an in-
crease in hematocrit without any signiﬁcant increase in platelets
[33]. Previously, it has been observed that BMT approach has
inherent deﬁciency in modeling the thrombocytosis phenotype in
mice. Several BMT models for JAK2V617F have been reported;
although these mice models showed polycythemia phonotype
but they did not show any increase in platelets [39–41]. In con-
trast, transgenic or knock-in mice models of Jak2V617F reproduc-
ibly produced all the features of PV including erythrocytosis,
leukocytosis and thrombocytosis [24,26–29]. Thus, the failure to
observe thrombocytosis in JAK2T875N transplanted mice does
not mean that the mutant is not capable of inducing AMKL. It is
also possible that JAK2T875N mutation is one of several genetic
events required for development of AMKL. Better mouse models,
such as transgenic or knock-in mouse models, of JAK2T875Nwould
determine if JAK2T875N is sufﬁcient to cause AMKL. However,
Studies by Mercher et al. have suggested that JAK2T875Nmay have
a more prominent effect on megakaryocytic lineage compared
with JAK2V617F [33]. In addition, compared with JAK2V617F,
JAK2K539L and JAK2T875N mutants did not induce a striking
leukocytosis [31,33]. The results from these mice models indicate
that different JAK2 mutants perturb hematopoietic signaling in a
different manner.
We used Ba/F3-EpoR cells expressing JAK2V617F, JAK2K539L
and JAK2T875N mutants to compare the biochemical and signaling
properties of JAK2 mutants. In addition, we expressed these JAK2
mutants in murine BM and compared their ability to transform
erythroid progenitors. We observed that JAK2 kinase domain
(JH1) mutant JAK2T875N has higher basal kinase activity than
the JH2 domain mutant JAK2V617F or the JH2-JH3 linker domain
mutant JAK2K539L (Fig. 1B). Autophosphorylation of JAK2 mutants
as determined by immunoblotting also matched with the results of
in vitro kinase assays (Figs. 1B and 4B). Several signaling mole-
cules/pathways, such as, Stat5, Stat3, Pim-1, Pim-2, Shp2, Gab2,
Akt and Erk, which are inducibly regulated by growth factors or
cytokines in hematopoietic cells, are constitutively activated in
cells expressing JAK2 mutants. JAK2T875N expression resulted in
signiﬁcantly more activation/induction of these signaling mole-
cules/pathways compared with the JAK2V617F or JAK2K539L mu-
tant (Fig. 4B and C). Haan et al., and Elliott et al., also have
compared the effects of these JAK2 mutants by expressing in
HEK293 cells [42,43]. However, they did not observe any signiﬁ-
cant difference in activation of the JAK2 mutants and their down-
stream signaling. It is possible that the effects of these JAK2
mutants on 293 cells and hematopoietic cells could be different.
Moreover, excessive overexpression of the JAK2 mutants (as usu-
ally occurs in 293 cells) might not allow us to see the differences
in their catalytic activity and downstream signaling pathways.
Also, previous studies did not compare the effects of these JAK2
mutants on hematopoietic progenitors. Our studies suggest that
different JAK2 mutants may have differential ability to transform
hematopoietic progenitors. Although JAK2T875N exhibited signiﬁ-
cantly more basal catalytic activity than the JAK2V617F or
JAK2K539L mutant (Fig. 1), it was less potent in transforming ery-
throid progenitors in the BM (Fig. 3). Thus, our data show that
transforming ability is not directly proportional to the catalytic (ki-
nase) activity of the JAK2 mutants. Similar results were observed
previously with the Noonan syndrome- and leukemia-associated
PTPN11 mutants, in which catalytic (phosphatase) activity of
PTPN11 mutants did not correlate with their transforming ability
and associated pathology [44].
Although all disease-associated JAK2 mutants have increased
basal kinase activity, the mechanisms underlying the constitutive
H. Zou et al. / FEBS Letters 585 (2011) 1007–1013 1011activation of these different JAK2 mutants remain elusive. Based on
the computer modeling, it was suggested that V617 residue in the
JH2 domain directly interacts with the JH1 kinase activation loop
to keep in an inactive conformation [45,46]. The V617F mutation
disrupts this critical interaction between JH2 and JH1 domainsA B
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Fig. 3. Transformation of erythroid progenitors by JAK2 mutants. BM from wild
type C57/BL6 mice were transduced with equal titer retroviruses expressing GFP
(vector), JAK2WT, JAK2V617F, JAK2K539L and JAK2T875N mutants and plated
(1  104 cells per dish) in methycellulose medium in the absence or presence of
Epo. CFU-E colonies were counted after 2 days. Results represent the means ± S.E.M.
of three independent experiments. Note that JAK2V617F and JAK2K539L expression
resulted in transformation of erythroid progenitors and gave rise to a large number
of CFU-E in the absence or presence of Epo. However, JAK2T875N was less potent in
transforming erythroid progenitors and gave rise to signiﬁcantly less CFU-E in the
absence or presence of Epo compared with JAK2V617F and JAK2K539L mutants
(JAK2V617F vs JAK2K539L, P < 0.05; JAK2V617F vs JAK2T875N, P < 0.0005;
JAK2K539L vs JAK2T875N, P < 0.0005).and results in constitutive activation of the JAK2 kinase [45,46].
The K539 residue lies within a region linking JH2 and JH3 domains.
Several residues within this linker region are believed to be impor-
tant to support the local conformation near V617 [46]. The K539L
mutation distorts the local conformation surrounding V617 and
causes signiﬁcant changes in the JH1/JH2 interface [46]. It has been
found that residues within the linker region between JH2 and JH3
domains are essential for interaction with EpoR and JAK2 activity
[38]. The T875 residue lies within the b2-b3 loop of the JH1 kinase
domain [33]. It was proposed that T875N mutation could poten-
tially disrupt the JH1/JH2 interface [33]. Computer based models
only helped to make some predictions on the structural effects of
JAK2 mutants. However, crystal structure of full-length JAK2 would
be required to better understand the mechanism of constitutive
activation of the JAK2 mutants and why some mutants are more
active than others.
Previous studies have demonstrated the requirement of
homodimeric type I cytokine receptor expression in JAK2V617F-
mediated transformation of hematopoietic cells [25,47]. Hemato-
poietic cell transformation by other JAK2 mutants (JAK2K539L,
JAK2T875N) also requires the presence of homodimeric type I cyto-
kine receptor [31,33]. This raises the possibility that differential
expression of homodimeric type I cytokine receptors in different
hematopoietic lineages and different levels of interaction of
the JAK2 mutants with the type I cytokine receptor may modulate
the disease phenotype. Indeed, we observed that PV and idio-
pathic erythrocytosis associated JAK2 mutants, JAK2V617F and
JAK2K539L, were more potent at transforming erythroid progeni-
tors and exhibited signiﬁcantly more interaction with the EpoRC
p-Shp2
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p-Gab2
Gab2
p-Erk1/2
Erk2
p-Akt
Akt
p-JAK2
p-Stat5
JAK2
Stat5
p-Stat3
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Pim-2
JAK2
EpoR
JAK2
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oR
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JAK2 mutants were starved in RPMI plus 0.5% BSA for 6 h. Cell lysates were prepared
ibody. (B) Activation of the components of the JAK-Stat signaling pathway, which
ng JAK2 mutants by immunoblotting using phospho-speciﬁc antibodies followed by
tream signaling molecules, such as Shp2, Gab2, Akt and Erk1/2, were analyzed by
tibodies against respective total proteins were used as loading controls. (D) Lysates
ith anti-EpoR antibody followed by immunoblotting with anti-JAK2 antibody. The
ctly immunoblotted with anti-JAK2 antibody to conﬁrm equivalent JAK2 expression
ﬁcantly less than with JAK2V617F or JAK2K539L.
1012 H. Zou et al. / FEBS Letters 585 (2011) 1007–1013compared with the AMKL-associated JAK2T875N mutant (Figs. 3
and 4D). We also have tried to analyze the interaction of different
JAK2 mutants with the EpoR in murine bone marrow cells. How-
ever, available EpoR antibodies failed to efﬁciently pull down
endogenous EpoR from the primary bone marrow cells (data not
shown). Nevertheless, we have provided evidence that different
JAK2 mutants have differences in their ability to interact with
the EpoR.
In conclusion, our studies show that disease-associated JAK2
mutants have differences in the kinase activity, and their biological
and signaling properties may also differ. However, the extent of
activation of the JAK2 kinase alone cannot predict the disease
phenotype of a JAK2 mutant. We have found evidence that
disease-associated JAK2 mutants have distinct intrinsic transform-
ing properties, which could be due to differential activation of
downstream signaling pathways and their speciﬁc interaction with
certain cytokine receptor. High-resolution crystal structure of
full-length JAK2 is yet to be resolved. Structural insights into the
effects of different JAK2 mutations would shed light in further
understanding the relationship between JAK2 activation, intracel-
lular signaling and pathology.
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